Clinical Trials Browser

INDUSTRY × Neuroendocrine Tumors × 30 days × Clear all

Carcinoid Tumors, Intestinal, Carcinoid Tumor, Neuroendocrine Tumors, Serotonin Syndrome

NCT07129252 2026-03-10

BRAVESST2

Phase 1/2 Recruiting

150 enrolled

EndocrineNET

Neoplasm Metastasis, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT02568267 2026-03-06

STARTRK-2

Phase 2 Active not recruiting

534 enrolled 1 FDA

BreastCNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidNETSarcomaThoracic

Thyroid Cancer, Papillary, Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Salivary Gland Neoplasms, Sarcoma, Colorectal Neoplasms, Lymphoma, Large-Cell, Anaplastic, Cholangiocarcinoma, Neuroendocrine Tumors

NCT06943755 2026-02-27

STELLAR-311

Phase 2/3 Recruiting

440 enrolled

EndocrineNET

Adenoma, Islet Cell, Neoplasm Metastasis, Neuroendocrine Tumors

NCT07314164 2026-02-27

Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior Treatment

Recruiting

150 enrolled

EndocrineNET

Neuroendocrine Tumors

NCT07377487 2026-02-20

INDIGO

Phase NA Recruiting

51 enrolled

EndocrineGastrointestinalNET

Carcinoma, Colonic Diseases, Digestive System Diseases, Digestive System Neoplasms, Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms, Neoplasm Metastasis, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Colorectal Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Clinical Trials

CAREFNDR

BRAVESST2

STARTRK-2

STELLAR-311

Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior Treatment

INDIGO